EDX Medical Group plc Stock: price and insider trades · United Kingdom
2 insiders bought €8,112 of shares over the last 90 days, the latest by Michael Hudson, filed 05 Nov 2026.
Cluster: 2 buyers in 30 daysEDX Medical Group plc: what insiders have been doing
EDX Medical Group plc is a listed company. Its directors and officers file their transactions with RNS (LSE). Over the twelve months to 6 November 2026, 2 filings were filed, from 2 insiders.
No insider sold shares on the market over the period. Instead, the filings list 2 purchases totalling €8,112, made by 2 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €6,077, bought by Michael Hudson and made public on 5 November 2026. The buyers include 1 chief executive.
In all, 2 purchases were made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The most recent open-market purchase was published on 5 November 2026, 3 days ago.
Compared with its exchange (834 companies, median 6 filings), a count of 2 filings is below the norm. Since 2026, the database holds 2 purchases and no sales by insiders of the company.
These figures are compiled from regulatory filings published by RNS (LSE). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended March 2026 · cache
- 75,000 shares@ £0.0677100.0% of flowXLON:AIMXISIN GB00BNDMJS47RNS:9860964-0Canonical exit: 2 Feb 2027 (T+90)
- 25,000 shares@ £0.068100.0% of flowXLON:AIMXISIN GB00BNDMJS47RNS:9860964-1Canonical exit: 2 Feb 2027 (T+90)
2 of 2 declarations
About EDX Medical Group plc
EDX Medical Group plc is a company listed on the London Stock Exchange, specializing in the medical sector. It focuses on the development and commercialization of innovative solutions for the diagnosis and treatment of diseases.
